{"id":"df8254e57b0b","type":"article","url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","title":"Canagliflozine en HF-uitkomsten bij behouden versus verminderde EF: CANVAS","title_en":"Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["canagliflozine","dapa-hf"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.119.040057","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.119.040057","authors":["Gemma A Figtree","Karin Rådholm","Terrance D Barrett","Vlado Perkovic","Kenneth W Mahaffey","Dick de Zeeuw","Greg Fulcher","David R Matthews","Wayne Shaw","Bruce Neal"],"significance":7,"published":"2019-05-28","source_date":"2019-05-28","image":"","kennis":[],"congress":"","summary_en":"This CANVAS analysis of heart failure outcomes stratified by ejection fraction showed that canagliflozin reduces heart failure events regardless of baseline LVEF, foreshadowing the later dedicated HFpEF trials with SGLT2 inhibitors.","created":"2026-07-03T10:27:57Z","updated":"2026-07-03T13:27:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"CANVAS analyse naar het effect van canagliflozine op HF-uitkomsten gestratificeerd naar behouden versus verminderde ejectiefractie bij diabetes type 2.","abstract_original":""}